13.23
서방형 약물 전달 시스템: 속도 프로그램형 II
속도 프로그램형 약물 전달 시스템은 치료적 농도를 유지하기 위해 약물을 제어된 방식으로 방출합니다. 주요 설계 유형에는 저장소형, 매트릭스형, 하이브리드형 시스템이 있습니다.
저장소형 시스템은 약물 방출을 조절하는 막으로 둘러싸인 약물 핵으로 구성됩니다. 비팽윤성 저장…
속도 프로그래밍된 약물 전달 시스템은 저장소, 매트릭스, 하이브리드 세 가지 설계를 따를 수 있습니다.
저류층 시스템은 약물 코어를 속도 조절 막 또는 막 안에 감싸 둡니다.
비부종형은 에틸 셀룰로오스와 폴리메타크릴레이트 폴리머를 사용하여 두께, 불용성, 느린 용해, 다공성을 통해 약물 방출을 조절합니다. 부기 조절형 유형은 종종 HPMC와 같은 고분자를 사용해 막 수화까지 약물 방출을 지연시킵니다.
매트릭스 시스템은 약물을 방출 지연 물질에 내장합니다.
친수성 매트릭스는 HPMC와 같은 팽창성 고분자를 사용하고, 소수성 매트릭스는 왁스나 에틸 셀룰로오스를 사용합니다. 소수성 매트릭스는 약물이 고분자에 혼합된 다공성일 수도 있고, 용융 고분자에 분산된 비다공성 매트릭스일 수도 있습니다.
하이브리드 시스템은 약물을 방출 지연 물질로 코팅된 매트릭스 안에 내장하고, 그 매트릭스에 방출 조절 폴리머로 추가로 코팅합니다. 이 설계는 저수지 시스템의 안정적인 방출과 매트릭스 장치의 내구성을 결합하여 약물 방출을 효과적으로 제어합니다.
View the full transcript and gain access to JoVE Core videos
Q1: What are the three main designs of rate-programmed drug delivery systems?
Rate-programmed drug delivery systems follow three designs: reservoir, matrix, and hybrid. Reservoir systems enclose the drug core within a rate-controlling membrane. Matrix systems embed the drug in a release-retarding material. Hybrid systems combine both approaches by embedding drug in a matrix and coating it with a polymer membrane, merging the consistent release of reservoir systems with the structural durability of matrix systems.
Q2: How do non-swelling reservoir systems control drug release?
Non-swelling reservoir systems use polymers like ethyl cellulose and polymethacrylates that do not hydrate in aqueous media. These polymers control drug release through membrane thickness, insolubility, slow dissolution, or porosity. This design is used in coated particles, pellets, or tablets to achieve predictable, sustained drug delivery without requiring membrane hydration.
Q3: What is the difference between hydrophilic and hydrophobic matrix systems?
Hydrophilic matrices use water-swellable polymers like HPMC that form porous structures and allow drug diffusion through the swollen matrix. Hydrophobic matrices use slowly soluble or insoluble materials like waxes or ethyl cellulose. Hydrophobic matrices can be porous, with drug mixed into polymer particles, or nonporous, with drug dispersed in molten polymer for controlled release.
Q4: How do swelling-controlled reservoir systems delay drug release?
Swelling-controlled reservoir systems use polymers such as HPMC that hydrate in aqueous media. Drug release begins only after the membrane absorbs water and hydrates, resulting in a delayed onset followed by steady release. This design allows precise timing of drug delivery initiation, making it useful for drugs requiring delayed therapeutic action.
Q5: What advantage do hybrid drug delivery systems offer over single-design systems?
Hybrid systems embed drug in a matrix and coat it with a polymer membrane, combining the consistent drug release of reservoir systems with the structural durability of matrix systems. This design provides superior control over drug delivery by leveraging the steady-state kinetics of reservoirs while maintaining the mechanical stability and longevity of matrix devices.
Q6: How does membrane thickness affect drug release in reservoir systems?
In non-swelling reservoir systems, membrane thickness is a critical parameter controlling drug release rate. Thicker membranes slow drug diffusion through the polymer, extending release duration, while thinner membranes accelerate release. By adjusting ethyl cellulose or polymethacrylate membrane thickness, manufacturers can precisely program drug release kinetics to match therapeutic requirements.
Q7: What role does porosity play in controlling drug release from matrix systems?
Porosity in matrix systems, particularly in hydrophobic matrices, creates pathways for drug diffusion and dissolution. Porous hydrophobic matrices mix drug and polymer particles, allowing fluid penetration and drug release through interconnected pores. Nonporous systems rely on drug solubility and polymer erosion, offering different release profiles suited to specific drug properties and therapeutic goals.